Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Brentuximab Vedotin in Relapsed/Refractory CD30+ T-cell Lymphoma
NCT05313243Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Jul 2023
- Primary completion
- Apr 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, brentuximab vedotin in T-cell lymphoma, sponsored by Yale University. Started Jul 2023; status: recruiting.
02
Drugs
pembrolizumabbrentuximab vedotin
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT05313243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313243.